204 related articles for article (PubMed ID: 31981740)
1. HPV induction of APOBEC3 enzymes mediate overall survival and response to cisplatin in head and neck cancer.
Conner KL; Shaik AN; Ekinci E; Kim S; Ruterbusch JJ; Cote ML; Patrick SM
DNA Repair (Amst); 2020 Mar; 87():102802. PubMed ID: 31981740
[TBL] [Abstract][Full Text] [Related]
2. APOBEC3 enzymes mediate efficacy of cisplatin and are epistatic with base excision repair and mismatch repair in platinum response.
Conner KL; Shaik AN; Marshall KA; Floyd AM; Ekinci E; Lindquist J; Sawant A; Lei W; Adolph MB; Chelico L; Siriwardena SU; Bhagwat A; Kim S; Cote ML; Patrick SM
NAR Cancer; 2020 Dec; 2(4):zcaa033. PubMed ID: 33196045
[TBL] [Abstract][Full Text] [Related]
3. Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity.
Kothandapani A; Sawant A; Dangeti VS; Sobol RW; Patrick SM
Nucleic Acids Res; 2013 Aug; 41(15):7332-43. PubMed ID: 23761438
[TBL] [Abstract][Full Text] [Related]
4. Electrochemotherapy with cisplatin or bleomycin in head and neck squamous cell carcinoma: Improved effectiveness of cisplatin in HPV-positive tumors.
Prevc A; Niksic Zakelj M; Kranjc S; Cemazar M; Scancar J; Kosjek T; Strojan P; Sersa G
Bioelectrochemistry; 2018 Oct; 123():248-254. PubMed ID: 29898433
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the impact of tumor HPV status on outcome in patients with locally advanced unresectable head and neck squamous cell carcinoma (HNSCC) receiving cisplatin, 5-fluorouracil with or without docetaxel: a subset analysis of EORTC 24971 study.
Psyrri A; Fortpied C; Koutsodontis G; Avgeris M; Kroupis C; Goutas N; Menis J; Herman L; Giurgea L; Remenár É; Degardin M; Pateras IS; Langendijk JA; van Herpen CML; Awada A; Germà-Lluch JR; Kienzer HR; Licitra L; Vermorken JB
Ann Oncol; 2017 Sep; 28(9):2213-2218. PubMed ID: 28651338
[TBL] [Abstract][Full Text] [Related]
6. PYHIN genes as potential biomarkers for prognosis of human papillomavirus-positive or -negative head and neck squamous cell carcinomas.
Riva G; Pecorari G; Biolatti M; Pautasso S; Lo Cigno I; Garzaro M; Dell'Oste V; Landolfo S
Mol Biol Rep; 2019 Jun; 46(3):3333-3347. PubMed ID: 30980272
[TBL] [Abstract][Full Text] [Related]
7. Human papillomavirus associated XPF deficiency increases alternative end joining and cisplatin sensitivity in head and neck squamous cell carcinoma.
Zuo N; Ma L; Liu T; Hu W; Luo Y; Meng H; Ren Q; Deng Y; Wei L; Liu Q
Oral Oncol; 2023 May; 140():106367. PubMed ID: 36996606
[TBL] [Abstract][Full Text] [Related]
8. Role of mismatch repair proteins in the processing of cisplatin interstrand cross-links.
Sawant A; Kothandapani A; Zhitkovich A; Sobol RW; Patrick SM
DNA Repair (Amst); 2015 Nov; 35():126-36. PubMed ID: 26519826
[TBL] [Abstract][Full Text] [Related]
9. Human papillomavirus DNA and p16 expression in Japanese patients with oropharyngeal squamous cell carcinoma.
Kawakami H; Okamoto I; Terao K; Sakai K; Suzuki M; Ueda S; Tanaka K; Kuwata K; Morita Y; Ono K; Nishio K; Nishimura Y; Doi K; Nakagawa K
Cancer Med; 2013 Dec; 2(6):933-41. PubMed ID: 24403267
[TBL] [Abstract][Full Text] [Related]
10. Chemotherapeutic alteration of VEGF-/PDGF- and PDGF-Rα/β expression by imatinib in HPV-transformed squamous cell carcinoma compared to HPV-negative HNSCC in vitro.
Schultz JD; Mühlheim K; Erben P; Hofheinz RD; Faber A; Thorn C; Sommer JU; Hörmann K; Sauter A
Oncol Rep; 2011 Nov; 26(5):1099-109. PubMed ID: 21805039
[TBL] [Abstract][Full Text] [Related]
11. Differential role of base excision repair proteins in mediating cisplatin cytotoxicity.
Sawant A; Floyd AM; Dangeti M; Lei W; Sobol RW; Patrick SM
DNA Repair (Amst); 2017 Mar; 51():46-59. PubMed ID: 28110804
[TBL] [Abstract][Full Text] [Related]
12. Human papillomavirus predicts the outcome following concomitant chemoradiotherapy in patients with head and neck squamous cell carcinomas.
Duray A; Descamps G; Decaestecker C; Sirtaine N; Gilles A; Khalifé M; Chantrain G; Depuydt CE; Delvenne P; Saussez S
Oncol Rep; 2013 Jul; 30(1):371-6. PubMed ID: 23603900
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemoradiation therapy with high-dose versus weekly cisplatin for resected, locally-advanced HPV/p16-positive and negative head and neck squamous cell carcinoma.
Geiger JL; Lazim AF; Walsh FJ; Foote RL; Moore EJ; Okuno SH; Olsen KD; Kasperbauer JL; Price DL; Garces YI; Ma DJ; Neben-Wittich MA; Molina JR; Garcia JJ; Price KA
Oral Oncol; 2014 Apr; 50(4):311-8. PubMed ID: 24467937
[TBL] [Abstract][Full Text] [Related]
14. APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development.
Henderson S; Chakravarthy A; Su X; Boshoff C; Fenton TR
Cell Rep; 2014 Jun; 7(6):1833-41. PubMed ID: 24910434
[TBL] [Abstract][Full Text] [Related]
15. Decreased SMAD4 expression is associated with induction of epithelial-to-mesenchymal transition and cetuximab resistance in head and neck squamous cell carcinoma.
Cheng H; Fertig EJ; Ozawa H; Hatakeyama H; Howard JD; Perez J; Considine M; Thakar M; Ranaweera R; Krigsfeld G; Chung CH
Cancer Biol Ther; 2015; 16(8):1252-8. PubMed ID: 26046389
[TBL] [Abstract][Full Text] [Related]
16. High-dose versus weekly cisplatin definitive chemoradiotherapy for HPV-related oropharyngeal squamous cell carcinoma of the head and neck.
Perez CA; Wu X; Amsbaugh MJ; Gosain R; Claudino WM; Yusuf M; Roberts T; Jain D; Jenson A; Khanal S; Silverman CI; Tennant P; Bumpous JM; Dunlap NE; Rai SN; Redman RA
Oral Oncol; 2017 Apr; 67():24-28. PubMed ID: 28351577
[TBL] [Abstract][Full Text] [Related]
17. Novel role of base excision repair in mediating cisplatin cytotoxicity.
Kothandapani A; Dangeti VS; Brown AR; Banze LA; Wang XH; Sobol RW; Patrick SM
J Biol Chem; 2011 Apr; 286(16):14564-74. PubMed ID: 21357694
[TBL] [Abstract][Full Text] [Related]
18. Acid sphingomyelinase activity as an indicator of the cell stress in HPV-positive and HPV-negative head and neck squamous cell carcinoma.
Gerle M; Medina TP; Gülses A; Chu H; Naujokat H; Wiltfang J; Açil Y
Med Oncol; 2018 Mar; 35(4):58. PubMed ID: 29564578
[TBL] [Abstract][Full Text] [Related]
19. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition.
Coppock JD; Wieking BG; Molinolo AA; Gutkind JS; Miskimins WK; Lee JH
Neoplasia; 2013 Jun; 15(6):620-30. PubMed ID: 23730210
[TBL] [Abstract][Full Text] [Related]
20. Similar cisplatin sensitivity of HPV-positive and -negative HNSCC cell lines.
Busch CJ; Becker B; Kriegs M; Gatzemeier F; Krüger K; Möckelmann N; Fritz G; Petersen C; Knecht R; Rothkamm K; Rieckmann T
Oncotarget; 2016 Jun; 7(24):35832-35842. PubMed ID: 27127883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
